Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, RI, USA.
Br J Cancer. 2018 Jan;118(2):294-298. doi: 10.1038/bjc.2017.378. Epub 2017 Oct 26.
Tetracycline is a photosensitising medication that increases skin vulnerability to UV-related damage.
We prospectively examined tetracycline use and risk of incident melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) based on 213 536 participants from the Nurses' Health Study (NHS), NHS2, and Health Professionals Follow-up Study. Information on ever use of tetracycline was asked via questionnaire. Diagnoses of melanoma and SCC were pathologically confirmed.
Tetracycline use was associated with a modestly increased risk of BCC (n=36 377), with a pooled hazard ratio (HR) of 1.11 (95% confidence interval (CI)=1.02-1.21, P-trend=0.05 by duration of use). Tetracycline use was not significantly associated with melanoma (n=1831, HR=1.09, 95% CI=0.94-1.27) or SCC (n=3332, HR=1.04, 95% CI=0.91-1.18) risk overall. However, we observed positive interactions between tetracycline use and adulthood UV exposure on SCC risk (P-interaction=0.05).
Tetracycline use was associated with a modestly increased risk of BCC, but was not associated with melanoma or SCC.
四环素是一种光敏药物，会增加皮肤对与紫外线相关的损伤的易感性。
我们前瞻性地研究了四环素的使用与黑色素瘤、鳞状细胞癌（SCC）和基底细胞癌（BCC）的发病风险之间的关系，研究对象来自护士健康研究（NHS）、NHS2 和健康专业人员随访研究中的 213536 名参与者。通过问卷询问了参与者是否曾使用过四环素。黑色素瘤和 SCC 的诊断均经过病理证实。
四环素的使用与 BCC 的发病风险呈中度增加相关（n=36377）， pooled hazard ratio (HR) 为 1.11（95% confidence interval (CI)=1.02-1.21，P-trend=0.05 按使用持续时间）。四环素的使用与黑色素瘤（n=1831，HR=1.09，95% CI=0.94-1.27）或 SCC（n=3332，HR=1.04，95% CI=0.91-1.18）风险总体上均无显著相关性。然而，我们观察到四环素的使用与成年期紫外线暴露之间存在 SCC 风险的正交互作用（P-interaction=0.05）。
四环素的使用与 BCC 的发病风险呈中度增加相关，但与黑色素瘤或 SCC 无关。
